Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.

Besins Healthcare has expanded its pharmaceutical operations with the acquisition of UniD Manufacturing, which specialises in long-acting drug delivery technologies.

Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.

The UK-US pharmaceuticals deal could cost the National Health Service (NHS) around £45bn ($60bn) within a decade and divert resources away from essential services, an analysis has suggested. The UK ...

Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios in mainland China.

Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US healthcare advertising, reflecting a changing of the guard in celebrity endorsements. The 23-time Grand Slam ...

Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.

Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m.

The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.

Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention.

Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital and industry converge at Campus Grand Parc.

WHO is sponsoring a trial testing drugs for Bundibugyo virus, while adding the first Ebola diagnostic test to its emergency use list.